Full-Time

Applications and Support Scientist

Molecular Diagnostics

Posted on 11/7/2025

Watchmaker Genomics

Watchmaker Genomics

201-500 employees

High-performance enzymes for genomics workflows

Compensation Overview

$83k - $87k/yr

+ Bonus + Equity

Boulder, CO, USA

In Person

In-office role in Boulder, CO; travel 20-30% to conferences and customer sites.

Category
Biology & Biotech (2)
,
Required Skills
Salesforce
Biochemistry
Requirements
  • Degree in molecular biology, biochemistry or related field required
  • BA/BS plus 6+ years experience, or MS plus 4+ years experience, or PhD plus 0-2+ years experience
  • Proven ability to execute molecular biology experiments including study design, lab work, and data interpretation with minimal supervision
  • Proven experience with molecular biology and enzymology assay development and optimization, preferably related to molecular diagnostics
  • Excellent molecular biology troubleshooting skills
  • Deep understanding of enzymology and nucleic acid detection techniques including extraction, reverse transcription, PCR, qPCR, isothermal amplification (RCA, RPA), reporter assays, etc. dPCR experience is a plus
  • Understanding of key performance indicators of clinical diagnostics assays including LOD, sensitivity, specificity, etc. Experience working in regulated environment a plus
  • Strong scientific communication skills. Comfortable with public speaking
  • Technical support experience preferred but not required
  • NGS knowledge or experience preferred but not required
  • Previous customer facetime and experience providing technical support are preferred but not required
  • Experience in biotech and a start-up environment are highly desirable
Responsibilities
  • Provide remote and in person technical support to molecular diagnostics and other customer segments
  • Record and track interactions with customers in Salesforce CRM
  • Design and execute experiments, and analyze resulting data in collaboration with Sales, Marketing, R&D, and Watchmaker customers, with minimal supervision, to develop protocols and applications for and to support products sold to molecular diagnostics and other customers
  • Generate content for and author customer-facing collateral demonstrating workflows and applications using Watchmaker products
  • Present technical content to customers remotely and in-person
  • Attend conferences to provide support to customers, promote Watchmaker products, present technical content to customers, and to learn about industry trends and new technologies where Watchmaker products can be leveraged
  • Travel to customer sites for trainings and to provide technical support
  • Contribute to new product development ideation through articulation of customer feedback and identification of unmet customer needs
Desired Qualifications
  • Experience in biotech and a start-up environment are highly desirable

Watchmaker Genomics develops specialized enzymes and tailored solutions used to read, write, and edit DNA for high-growth molecular biology companies. These enzymes act as biological tools that drive critical workflows like DNA sequencing and synthesis, supported by custom manufacturing and quality control processes. The company distinguishes itself through a leadership team with deep industry experience in enzyme supply chains and a focus on creating bespoke products through collaborative research partnerships. Its goal is to accelerate genomic research and diagnostics by providing high-performance tools that improve the speed and accuracy of genetic data processing.

Company Size

201-500

Company Stage

Series A

Total Funding

$48.3M

Headquarters

Boulder, Colorado

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Volta Labs Callisto Kit launched February 2026 boosts PCR-free WGS adoption in clinical labs.
  • Visby Medical partnership advances at-home respiratory pathogen tests using StellarScript HT+.
  • Promega licenses novel reverse transcriptase September 2025 for enhanced RNA assays.

What critics are saying

  • New England Biolabs undercuts with lower-cost NGS enzymes, eroding share in Q1 2026.
  • Ultima Genomics UG 100 integrates proprietary methylation chemistry, stranding TAPS+ in 12 months.
  • Qiagen relaunches Kapa IP PCR-free enzymes, capturing Revvity automation partnerships in 2026.

What makes Watchmaker Genomics unique

  • TAPS+ unites genetic and epigenetic readouts from single DNA molecules without bisulfite damage.
  • StellarScript HT+ reverse transcriptase excels in inhibitor tolerance for unprocessed clinical samples.
  • Engineered enzymes enable PCR-free WGS with uniform GC-rich coverage in automated kits.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Flexible Work Hours

Paid Parental Leave

401(k) Retirement Plan

401(k) Company Match

Employee Assistance Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
360Dx
Apr 20th, 2026
Watchmaker Genomics takes aim at infectious disease dx with new qpcr, isothermal products at ESCMID.

Watchmaker Genomics takes aim at infectious disease dx with new qpcr, isothermal products at ESCMID. MUNICH - Watchmaker Genomics, a company known more for its engineered enzymes for use in next-generation sequencing and cancer research applications, this week showcased its newer products for infectious disease molecular diagnostics developers here at the European Society of Clinical Microbiology and Infectious Diseases global congress (ESCMID Global). Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

PR Newswire
Feb 23rd, 2026
Volta Labs and Watchmaker Genomics launch Callisto Complete Kit for automated PCR-free DNA sequencing

Volta Labs and Watchmaker Genomics have launched the Callisto Complete Kit for DNA EF Library Prep at the AGBT 2026 conference in Orlando. The solution combines Watchmaker's NGS sample preparation chemistry with Volta's digital fluidics automation to deliver fully automated, PCR-free whole genome sequencing library preparation. The kit targets clinical research and translational laboratories requiring mid-throughput solutions. PCR-free workflows minimise amplification bias and sequencing artefacts whilst enabling more uniform genome coverage, particularly in GC-rich regions. The automation eliminates manual liquid handling and reduces operator variability. "Labs can run PCR-free whole genome sequencing workflows in a push-button format, delivering consistent, high-quality results," said Udayan Umapathi, CEO of Volta Labs. The companies hosted a joint presentation at AGBT 2026 on 24 February.

Virtual Press Office
Feb 23rd, 2026
Volta Labs and Watchmaker Genomics Partner to Introduce Callisto(TM) Complete Kit for DNA EF Library Prep at AGBT 2026

Volta Labs and Watchmaker Genomics partner to introduce Callisto(TM) Complete Kit for DNA EF Library Prep at AGBT 2026. BOSTON and BOULDER, Colo., Feb. 23, 2026 /PRNewswire/ - At the Advances in Genome Biology and Technology (AGBT) General Meeting 2026 in Orlando, FL, Volta Labs, a leader in next-generation sequencing (NGS) sample preparation automation, today announced the launch of the Callisto(TM) Complete Kit for DNA EF Library Prep. The new solution pairs Watchmaker Genomics' best-in-class NGS sample preparation chemistry with Volta's digital fluidics automation to deliver a fully automated, PCR-free whole genome sequencing (WGS) library preparation workflow. As whole genome sequencing continues to expand across clinical research and translational settings, PCR-free workflows are increasingly preferred to minimize amplification bias, reduce sequencing artifacts, and enable more uniform genome coverage, particularly in GC-rich regions. However, executing PCR-free library preparation demands precision and reproducibility, making automation critical for labs seeking consistent results without increasing staffing burden. By eliminating manual liquid handling and reducing operator variability, the Callisto(TM) Complete Kit enables laboratories to generate reproducible, high-quality libraries while freeing technical staff to focus on higher-value work. "We designed Callisto to make sequencing sample preparation simpler and more accessible," said Udayan Umapathi, CEO of Volta Labs. "With the Callisto(TM) Complete Kit for DNA EF Library Prep, powered by Watchmaker chemistry, labs can run PCR-free whole genome sequencing workflows in a push-button format, delivering consistent, high-quality results in a practical mid-throughput range." "PCR-free whole genome sequencing demands both high-performance chemistry and workflow precision," said Trey Foskett, CEO of Watchmaker Genomics. "For clinical and translational laboratories that require push-button solutions with dependable performance but do not operate at a high-throughput scale, the Callisto(TM) Complete Kit offers a simple and streamlined path to implementing PCR-free WGS with confidence." To mark the launch, Volta Labs and Watchmaker Genomics will host a joint in suite presentation at AGBT 2026 on February 24 at 8:30 a.m. in the Fulton Suite, where attendees can learn more about the Callisto(TM) Complete Kit for DNA EF Library Prep, see the automated PCR-free WGS workflow in action, and hear directly from both teams. About Volta Labs Volta Labs is pioneering a new future of sequencing sample preparation by combining digital fluidics, modular workflows, and full walk-away automation in a single platform. Callisto(TM) enables high-quality, reproducible NGS library preparation for whole-genome, targeted, and custom applications. Volta Labs is headquartered in Boston, Massachusetts. About Watchmaker Genomics Watchmaker Genomics is a life sciences company focused on developing high-performance tools that empower genomic research and clinical applications. Leveraging expertise in protein engineering and next-generation sequencing, Watchmaker delivers precision reagents and platforms that enable superior accuracy, efficiency, and cost-effectiveness in molecular analysis. The company is dedicated to advancing breakthrough technologies to support innovations in cancer detection, epigenetics, and liquid biopsy applications. Media Contacts Volta Labs Nicole Ellis Ovadia Director of Strategic Marketing [email protected] Watchmaker Genomics Jen Pavlica Associate Director, Product Marketing [email protected] SOURCE Volta Labs Inc.

360Dx
Feb 5th, 2026
Visby Medical, Watchmaker Genomics Partner to Develop At-Home Respiratory Pathogen Detection Tests

Visby Medical, Watchmaker Genomics partner to develop at-home respiratory pathogen detection tests. NEW YORK - Visby Medical said on Thursday that it has inked a partnership with Watchmaker Genomics to develop diagnostic tests for detecting respiratory pathogens in the at-home setting. To read the full story...

Medical Product Outsourcing
Feb 5th, 2026
Visby Medical, Watchmaker Genomics Collaborate on Respiratory Pathogen Detection

Visby Medical, Watchmaker Genomics collaborate on respiratory pathogen detection. The partnership pairs Visby Medical's instrument-free PCR testing tech with Watchmaker's expertise in engineering enzymes. Visby Medical has forged a strategic collaboration with Watchmaker Genomics to develop next-generation diagnostic tests for respiratory pathogen detection in the at-home setting. The partnership pairs Visby Medical's instrument-free PCR testing technology - billed as the first and only of its kind - with Watchmaker's expertise in engineering enzymes to address application-specific performance gaps. "Recent increases in COVID cases involving new strains and the current flu season highlight the need for tests that are reliable and fast," explained Visby Medical Chief Medical Officer Gary Schoolnik, M.D., infectious disease expert and professor of Medicine at Stanford University. "Every patient and their healthcare professional needs test results they can have confidence in so that appropriate treatment decisions can be made quickly for optimal recovery, infection control, and the judicious use of antibiotics. The essential tool is rapid PCR testing that does not require instruments or extended lab preparation." Clinical samples collected from patients for at-home testing are typically unprocessed, making them vulnerable to molecular inhibitors that can reduce signal strength and lower assay sensitivity. The need for rapid results in the at-home setting also places unique performance demands on the assays and the enzymes they rely on. "This partnership underscores Watchmaker's commitment to delivering solutions that address real issues in clinically relevant applications, and we are excited to work with Visby Medical to provide a unique and urgently needed solution that utilizes their PCR platform," Watchmaker Genomics Co-Founder/CEO Trey Foskett stated. "Our StellarScript HT+ Reverse Transcriptase is engineered to be highly inhibitor-tolerant and thermostable - the novel enzyme is an excellent fit for rapid pathogen detection." Watchmaker Genomics applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. The company combines domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth clinical genomics applications. Watchmaker's product portfolio includes enzymes and kits for next-generation sequencing, synthetic biology, and molecular diagnostics. Founded in 2012, Visby Medical is striving to revolutionize infectious disease diagnosis by empowering users to accurately test for infections anywhere, anytime, with laboratory accuracy. The company's proprietary technology platform delivers true PCR results in under 30 minutes through instrument-free, single-use PCR tests that fit in the palm of the hand. Currently, Visby Medical offers U.S. Food and Drug Administration-cleared tests for sexually transmitted infections (STIs) directly to consumers. Visby Medical is actively expanding its platform targeting other critical respiratory and sexual health pathogens.

INACTIVE